- Conditions
- Infantile Hemangiomas
- Interventions
- Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Month to 8 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,057
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Connective Tissue Disease, Dissecting Aneurysm, Ehlers Danlos Syndrome, Marfan Syndrome, Nail Patella Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney, Polycystic
- Interventions
- Lisinopril, Telmisartan, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 15 Years to 64 Years
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
- Interventions
- Steen Solution™, Conventional Lung Transplant
- Device · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Congenital Disorders of Glycosylation
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Secondary Myelofibrosis
- Interventions
- filgrastim, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Procedure
- Lead sponsor
- The Canadian Blood and Marrow Transplant Group
- Network
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
- Interventions
- QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
- Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hypoxia-Ischemia, Brain, Periventricular Leukomalacia
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
- Interventions
- ROC-101
- Drug
- Lead sponsor
- AllRock Bio, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 8 more
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
- Interventions
- anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Duarte, California
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- ESRD, Fabry Disease, Rare Diseases, Kidney Diseases, End Stage Renal Disease, Genetic Diseases, X-Linked
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
- Interventions
- Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- Up to 69 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 2 Years to 120 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Chronic Lymphocytic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Renal Cell Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Splenic Marginal Zone Lymphoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Waldenström Macroglobulinemia
- Interventions
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, cyclosporine, mycophenolate mofetil, pharmacological study, laboratory biomarker analysis
- Drug · Radiation · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 3 more
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more
- Conditions
- Aortic Aneurysm, Aortic Dissection, Bicuspid Aortic Valve (BAV), Heart Failure, Cardiovascular Diseases
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 15,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2053
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- DX-2930, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Chronic Kidney Disease
- Interventions
- PRT-201, Placebo
- Drug
- Lead sponsor
- Proteon Therapeutics
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
- Conditions
- Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Fabry Disease
- Interventions
- Fabrazyme (agalsidase beta)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Coral Springs, Florida + 11 more
- Conditions
- Vascular Ehlers-Danlos Syndrome
- Interventions
- Heartmath Intervention, Control Group
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fabry Disease
- Interventions
- Measures of arterial stiffness and endothelial function, Ambulatory blood pressure monitoring, Cardiopulmonary exercise testing (CPET), Serum and urine biomarkers
- Diagnostic Test
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio